"Designing Growth Strategies is in our DNA"
Upsurge in livestock diseases impose a considerable burden on the economy and agriculture of many countries. Use of livestock vaccines can help in preventing a wide range of disease in animals as well as spread of these diseases to humans. Livestock vaccines, commonly available in live attenuated or inactivated forms, have been utilized successfully in the prevention of diseases in animals and humans. The potential benefits of livestock vaccines include improvement in animal welfare and public health.
Many clinical studies are undertaken to develop vaccines for various livestock disease using new vaccine technologies such as marker vaccine, split –product, isolated protein or peptide and nucleic acid approaches. Furthermore, global livestock vaccines market has paved its way for many key mergers and acquisitions. For example, in 2016, Elanco U.S., Inc., a subsidiary company of Eli Lilly and Company acquired the U.S. canine, feline and rabies animal vaccines portfolio of Boehringer Ingelheim Vetmedica, Inc., one of the major players in animal health.
To gain extensive insights into the market, Request for Customization
The growth in global livestock vaccines market is being driven by the increased demand for recombinant vaccine, DNA vaccines, multivalent vaccines and others. The outbreak of diseases such as the African Swine Fever (ASF), affecting millions of pigs in China, Vietnam, Cambodia, and other south-east Asian countries in 2018, and Mycoplasma bovis infections among cattle in 2018, in New Zealand, is among the major factors propelling the demand for vaccines in the global market. In addition, the increasing government initiatives to prevent the spread of zoonotic diseases is also expected to fuel the growth in global livestock vaccines market during the forecast years.
However, lack of availability of vaccines, and inoperative vaccination centres in emerging countries especially India, China, and Brazil, which hold a dominant proportion of livestock animals, is a major restraining factor in the global livestock vaccines market.
The major companies covered in the global livestock vaccines market report include Merck & Co., Inc., Pfizer Inc., AgriLabs, Zoetis, Novartis AG, Boehringer Ingelheim, Bayer AG, Eli Lilly and Company, Virbac, Neogen Corporation, ImmuCell Corporation and other players.
ATTRIBUTE | DETAILS |
By Animal Type |
|
By Vaccine Type |
|
By Route of Administration |
|
By Disease Indication |
|
By Distribution Channel |
|
By Geography |
|
As per the current livestock vaccines market trends, attenuated vaccines among the vaccine type accounted for dominant market share in the global livestock vaccines market owing to benefits such as higher efficiency and long-term prevention.
The global livestock vaccines market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the livestock vaccines market followed by Europe. The livestock vaccines market is anticipated to expand in North America during the forecast years owing to awareness regarding the prevention of animal-to-human transmission of diseases, higher demand for meat, and investment in research and development in animal vaccines. Asia Pacific is anticipated to grow at a significant CAGR during the forecast period due to the rising prevalence of livestock diseases such as foot-and-mouth disease (FMD) and highly pathogenic avian influenza (HPAI). Additionally, the increasing incidence of zoonotic diseases, initiatives by government organisations and animal associations to provide access to livestock vaccines, are expected to fuel growth of the livestock vaccines market in the Asia Pacific region. The livestock vaccines market in Middle East & Africa and Latin America is in the nascent stage; however, it is anticipated to grow at a moderate CAGR during the forecast period.